Abstract:
Schistosomiasis is a WHO-listed Neglected Tropical Disease characterized by the blood-dwelling trematode parasites of the genus Schistosoma. Currently, all schistosomiasis vaccine candidates based on recombinant subunit antigens have encountered setbacks at various stages of clinical trials, underscoring the formidable challenges in vaccine development. Critically, these subunit vaccines lack the three-dimensional macrostructure necessary for optimal recognition by B cells as pathogenic entities. Drawing inspiration from Professor Mark Howarth’s group’s SpyCatcher-SpyTag system, our objective is to conjugate schistosomiasis antigens onto virus-like-particle (VLP) scaffolds to create high-density antigen nanoparticles that are readily recognized as immunogenic by the immune system. Together with a batch of novel antigens discovered through unbiased phage display in January 2024, our aim is to present a diverse range of schistosomiasis antigens on VLPs and thoroughly characterize their biochemical properties.
Biography:
Symonne Liu graduated from the University of Chicago with a double major in Molecular Engineering and Biological Sciences. With a strong background in genetics, bioengineering, synthetic biology, and computational biology, Symonne has been actively involved in research projects spanning RNA interference pathways, retrovirus resistance mechanisms, and Schistosomiasis vaccine development. At the Golovkina Lab, Symonne investigates the mechanism of retrovirus infection in congenic mouse lines. As a leader in UChicago Gene Hackers, Symonne spearheaded the development of a novel virus-like particle vaccine for Schistosomiasis and collaborated with the NIH-funded Schistosomiasis Resource Center to conduct immunogenic studies. Symonne is also a prominent figure in the field of synthetic biology, leading a team that was nominated for the Best Project in Infectious Diseases at an international synthetic biology competition. Their expertise in designing and engineering biological systems has contributed to groundbreaking advancements in vaccine development and therapeutic strategies. Beyond research, Symonne has engaged in biomedical entrepreneurship and pharmacogenomics initiatives, bridging the gap between lab discoveries and clinical applications. As the founder and board member of the Chicagoland Virology Journal Club, they are dedicated to fostering STEM education and scientific communication on infectious diseases.
